Related Experiment Video

Updated: Mar 25, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer

Archana Balakrishnan1, Arpita Vyas1, Kaivalya Deshpande1

  • 1Archana Balakrishnan, Arpita Vyas, Kaivalya Deshpande, College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States.

World Journal of Gastroenterology
|February 23, 2016
PubMed

Insights

New CDK inhibitors show promise for treating colorectal cancer by blocking cell growth. This overview details emerging drugs targeting cyclin-dependent kinases (CDKs) in clinical trials for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Colorectal cancer is a leading cause of cancer mortality globally, necessitating novel chemotherapeutic agents.
  • Cell cycle regulation by cyclin-dependent kinases (CDKs) and cyclins is crucial for controlling cellular proliferation.
  • Uncontrolled cell growth is a hallmark of cancers, including colorectal cancer.

Purpose of the Study:

  • To provide an overview of the emerging class of cyclin-dependent kinase (CDK) inhibitors.
  • To discuss the potential of CDK inhibitors as anti-cancer drugs for colorectal cancer.
  • To list CDK inhibitors currently undergoing clinical trials.

Main Methods:

  • Review of preclinical and clinical studies on CDK inhibitors.
  • Analysis of the mechanism of action of CDK inhibitors in blocking cell cycle progression.
  • Compilation of a list of CDK inhibitors in active clinical trials.

Main Results:

  • CDK inhibitors represent a promising new therapeutic strategy for cancer treatment.
  • These inhibitors function by targeting the cell cycle machinery, specifically CDKs.
  • Several CDK inhibitors are progressing through various phases of clinical trials.

Conclusions:

  • CDK inhibitors hold significant potential as chemotherapeutic agents against colorectal cancer.
  • Targeting CDKs offers a rational approach to inhibit uncontrolled cellular proliferation in cancer.
  • The ongoing clinical trials will determine the efficacy and safety of these emerging drugs.
Keywords:
Colorectal cancerCyclinCyclin dependent kinase inhibitor

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K